Compare PKOH & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKOH | EVMN |
|---|---|---|
| Founded | 1907 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.5M | 409.2M |
| IPO Year | 1994 | N/A |
| Metric | PKOH | EVMN |
|---|---|---|
| Price | $38.47 | $11.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $37.00 | ★ $43.88 |
| AVG Volume (30 Days) | 81.1K | ★ 1.4M |
| Earning Date | 05-06-2026 | 06-11-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $1,599,100,000.00 | N/A |
| Revenue This Year | $7.87 | N/A |
| Revenue Next Year | $3.42 | N/A |
| P/E Ratio | $66.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.52 | $10.47 |
| 52 Week High | $39.69 | $33.20 |
| Indicator | PKOH | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 61.16 | 32.16 |
| Support Level | $33.76 | N/A |
| Resistance Level | $39.33 | $21.21 |
| Average True Range (ATR) | 1.66 | 0.98 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 81.52 | 20.60 |
Park-Ohio Holdings Corp is a diversified international company offering its clients supply chain management outsourcing services, capital equipment used on their production lines, and manufactured components used to assemble their products. The company operates through three reportable segments: Supply Technologies, Assembly Components, and Engineered Products. Maximum revenue is generated from the Supply Technologies segment, which is mainly engaged in sourcing, planning, and procurement of several production components, including fasteners, pins, nuts, bolts, valves, hoses, wire harnesses, clamps and fittings, etc. Geographically, the company generates maximum revenue from its business in the United States, followed by Europe, Asia, Mexico, Canada, and other regions.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.